Cancer Drug Dosing Is Changing: The Maximum Tolerated Dose Is No Longer Enough
In this article
Why It Matters
Long accepted as the default in oncology, the maximum tolerated dose (MTD)reflects the logic of the cytotoxic chemotherapy era: higher dose = greater effect. With modern targeted therapies and immunotherapies , however, this relationship often plateaus: increasing the dose may not improve efficacy, while toxicity becomes more pronounced and time on treatment may shorten.
A joint ASCO and FDAreport published on 24 July 2025 in the Journal of Clinical Oncologytherefore recommends making preapproval dose optimizationstandard practice. The aim is to find the dose balancing the greatest patient benefit with the fewest side effects , identifying the optimal dose rather than pushing for the highest dose. This involves randomized multiarm dose studies, systematic recording of patient-reported outcomes (PROs) and chronic/low-grade toxicities , and clarification through PK/PD of the dose–exposure–response relationship.
Here, PK/PD analysisexamines the dose's resulting exposure (concentration–time curve, Cmax/AUC) and how that exposure translates into efficacy and toxicity , identifying thresholds for adequate efficacy and side effects. It provides a quantitative basis for optimal dose selection in clinical trials.
Why Now?
The findings are concerning for both patients and clinical teams : in metastatic breast cancer, 86%report at least one serious treatment-related side effect, and 66%require dose reductions. Many oncologists also prefer a lower starting dose to limit toxicity. This calls for replacing the high-dose reflex with patient-centered dose selection .
- What Is Changing? Moving from a single MTD-focused dose to an evidence-based optimal dose range .
- How? Randomized dose comparisons, broader eligibility criteria, and integration of PRO and PK/PD data.
- Who Benefits? Patients: better quality of life and longer time on treatment; clinical teams: more predictable toxicity and clearer decision support.
📚 Contents
Why Do We Need a New Dosing Approach?
MTD (maximum tolerated dose) was developed in the conventional chemotherapy era. The logic was simple: higher dose = greater effect. But with today's targeted therapies and immunotherapies , this relationship often does not hold.
- A higher dose often fails to produce a greater tumor response .
- In contrast, side effects increase markedly and patients are less able to remain on treatment.
📊 Key Finding: In a survey of patients with metastatic breast cancer, 86% reported at least one serious treatment-related side effect, while 66%had required dose reduction.
Oncologists Face Challenges Too
The MTD approach burdens physicians as well as patients. An ASCO survey of 367 oncologists treating metastatic cancer found:
- 65% considered a lower starting dose acceptable to limit toxicity.
- 93% said they informed patients when starting at a lower dose.
- 89% reported regularly discussing the efficacy–toxicity balance with patients.
📌 Scientific Insight: The Clinical Challenge
The traditional MTD approach largely focuses on severe toxicities during the first treatment cycle . Yet many side effects, such as Grade 2 diarrhea: 4–6 additional bowel movements daily) emerge in later cycles and can lead to treatment discontinuation .
Dose–Response and Dose–Toxicity Curves for Different Cancer Drugs
Figure 1. The diagram compares dose–response and dose–toxicity relationships across three drug classes: cytotoxic drugs (chemotherapy), where response and side effects rise in parallel with dose, versus targeted therapies and immunotherapies , which have a wider therapeutic window . This means efficacy may be maintained at lower doses while unnecessary toxicity is avoided.
Why Are Postapproval Studies Insufficient?
The FDA's frequent deferral of dose research until after approval causes several problems:
- Studies may take an average of 5 years to complete .
- During this time, many patients receive suboptimal doses .
- Results often do not translate into label changes .
Therefore, dose optimization studies should be completed before approval .
The New Era's 5 Scientific Principles
-
Collect More Comprehensive Safety and Patient-Reported Data
- Monitor long-term, low-grade side effects as well as serious toxicities, including PROs.
-
Adapt Trial Designs to Drug Type and Patient Population
- For example, immunotherapy dose–toxicity curves are often flat; escalating to MTD may be unnecessary.
-
Use Modern Randomized Trials Comparing Multiple Doses
- Systematically assess alternatives rather than recommending a single dose.
-
Include Broader Patient Populations
- Reduce unnecessary exclusions based on age, performance status and comorbidities.
-
Strengthen Pharmacological Analyses
- Clarify dose–exposure–response relationships through PK/PD approaches.
📌 Scientific Insight: Methodology
Traditional Phase I studies often concluded with one recommended dose (RP2D) from small cohorts . The new approach aims to identify the optimum using randomized, multiarm dose-ranging designs and pharmacokinetic–pharmacodynamic modeling to determine the optimal dose .
Why the Paradigm Shift Matters
The change means more than safer treatments ; for patients it also aims to:
- Preserve quality of life,
- Allow treatment to be tolerated longer,
- Reduce side effect-related treatment interruptions .
The FDA's Project Optimus initiative supports patient-centered dose selection.
🧾 Conclusion
In cancer treatment, "high dose, high benefit" is evolving toward "optimal dose = greatest benefit + fewest side effects" . This transformation signals a new treatment era for patients and oncologists: safer, more effective and more humane care.
Sources
DOI:10.1200/JCO-25-00488
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.